Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats

Planta Medica

Volumn 77, Issue 3, 2011, Pages 231-235

  Qi, Zhigang ^a   Xue, Jie ^a   Zhang, Yan ^b   Wang, Hengbin ^c   Xie, Meilin ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University   (China)

^c Changshu Leiyunshang Pharmaceutical Co Ltd   (China)

Author keywords

adiponectin; Apiaceae; Cnidium monnieri; fatty liver; insulin resistance; osthole; PPAR

Indexed keywords

ADIPONECTIN; CHOLESTEROL; FATTY ACID; FENOFIBRATE; GLUCOSE; INSULIN; OSTHOLE; ROSIGLITAZONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE DIET; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FATTY LIVER; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; LIVER WEIGHT; MALE; NONHUMAN; PROTEIN SECRETION; RAT; TISSUE LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; ANIMALS; BLOOD GLUCOSE; CNIDIUM; COUMARINS; DIETARY FATS; DIETARY SUCROSE; FATTY LIVER; FENOFIBRATE; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; LIPIDS; LIVER; MALE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PHYTOTHERAPY; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES;

APIACEAE; CNIDIUM MONNIERI; RATTUS;

EID: 79551686501     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0030-1250268     Document Type: Article

References (28)

1. Biddinger S B., Kahn C R. From mice to men, insights into the insulin resistance syndromes. Annu Rev Physiol 2006 68 123-158
2. Hotamisligil G S. Inf (Pubitemid 46024993)
3. Regazzetti C, Peraldi P, Gremeaux T, Najem-Lendom R, Ben-Sahra I, Cormont M, Bost F, Marchand-Brustel Y L., Tanti J F., Giorgetti-Peraldi S. Hypoxia decreases insulin signaling pathways in adipocytes. Diabetes 2009 58 95-103
4. Mendez-Sanchez N, Arrese M, Zamora-Valdes D, Uribe M. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int 2007 27 423-433 (Pubitemid 46534563)
5. Utzschneider K M., Kahn S E. Review: the role of insulin resistance in nonalcoholic fatty liver disease. Clin Endocrinol Metab 2006 91 4753-4761 (Pubitemid 44917301)
6. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999 20 649-688 (Pubitemid 30650602)
7. Reddy J K. Nonalcoholic steatosis and steatohepatitis: III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2001 281 G1333-G1339
8. Jay M A., Ren J. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr Diabetes Rev 2007 3 33-39 (Pubitemid 46592792)
9. Ferreira A V., Parreira G G., Porto L C., Mario E G., Delpuerto H L., Martins A S., Botion L M. Fenofibrate prevents orotic acid-induced hepatic steatosis in rats. Life Sci 2008 82 876-883
10. Fernández-Miranda C, Pérez-Carreras M, Colina F, López-Alonso G, Vargas C, Solís-Herruzo J A. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Digest Liver Dis 2008 40 200-205 (Pubitemid 351181792)
11. Neuschwander-Tetri B A., Brunt E M., Wehmeier K R., Sponseller C A., Hampton K, Bacon B R. Interim results of a pilot study demonstrating the early effects of the PPAR- ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 2003 38 434-440 (Pubitemid 36399245)
12. Parra J L., Reddy K R. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis 2003 7 415-433 (Pubitemid 36807740)
13. Nesto R W., Bell D, Bonow R O., Fonseca V, Grundy S M., Horton E S., Winter M L., Porte D, Semenkovich C F., Smith S, Young L H., Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004 27 256-263 (Pubitemid 38196741)
14. Nissen S E., Wolski K, Topol E J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. Am Med Assoc 2005 294 2581-2586 (Pubitemid 41697247)
15. Chang F, Jaber L A., Berlie H D., O'Connell M B. Evolution of peroxisome proliferator-activated receptor agonists. Ann Pharmacother 2007 41 973-983 (Pubitemid 46917624)
16. Song F, Xie M L., Zhu L J., Zhang K P., Xue J, Gu Z L. Experimental study of osthole on treatment of hyperlipidemic and alcoholic fatty liver in animals. World J Gastroenterol 2006 12 4359-4363 (Pubitemid 44194529)
17. Zhang Y, Xie M L., Zhu L J., Gu Z L. Therapeutic effect of osthole on hyperlipidemic fatty liver in rats. Acta Pharmacol Sin 2007 28 398-403
18. Sun F, Xie M L., Zhu L J., Xue J, Gu Z L. Inhibitory effect of osthole on alcohol-induced fatty liver in mice. Dig Liver Dis 2009 41 127-133
19. Zhang Y, Xie M L., Xue J, Gu Z L. Osthole improves fat milk-induced fatty liver in rats: modulation of hepatic PPAR-alpha/gamma-mediated lipogenic gene expression. Planta Med 2007 73 718-724 (Pubitemid 47234612)
20. Zhang Y, Xie M L., Xue J, Gu Z L. Osthole regulates enzyme protein expression of CYP7A1 and DGAT2 via activation of PPARalpha/gamma in fat milk-induced fatty liver rats. Asian Nat Prod Res 2008 10 807-812
21. Sun F, Xie M L., Xue J, Wang H B. Osthole regulates hepatic PPAR -mediated lipogenic gene expression in alcoholic fatty liver murine. Phytomedicine 2009 17 669-673
22. Liang H J., Suk F M., Wang C K., Hung L F., Liu D Z., Chen N Q., Chen Y C., Chang C C., Liang Y C. Osthole, a potential antidiabetic agent, alleviates hyperglycemia in db/db mice. Chem Biol Interact 2009 181 309-315
23. Zou Y H., Li J, Lu C, Wang J Q., Ge J F., Huang Y, Zhang L, Wang Y Y. High-fat emulsion-induced rat model of nonalcoholic steatohepatitis. Life Sci 2006 79 1100-1107 (Pubitemid 44102717)
24. Spranger J, Kroke A, Mohlig M, Bergmann M M., Ristow M, Boeing H, Pfeiffer A F. H. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003 361 226-228 (Pubitemid 36126226)
25. Yesilova Z, Yaman H, Oktenli C, Ozcan A, Uygun A, Cakir E, Sanisoglu S Y., Erdil A, Ates Y, Aslan M, Musabak U, Erbil M K., Karaeren N, Dagalp K. Systemic markers of lipid peroxidation and antioxidants in patients with non-alcoholic fatty liver disease. Am J Gastroenterol 2005 100 850-855 (Pubitemid 40592378)
26. Fruebis J, Tsao T S., Javorschi S, Ebbets-Reed D, Erickson M R., Yen F T., Bihain B E., Lodish H F. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001 98 2005-2010 (Pubitemid 32165613)
27. Chinetti G, Zawadski C, Fruchart J C., Staels B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem Biophys Res Commun 2004 314 151-158 (Pubitemid 38058382)
28. Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, Kadowaki T. Peroxisome proliferator-activated receptor (PPAR) alpha activation increases adiponectin receptors and reduces obesity related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 2005 54 3358-3370 (Pubitemid 43334324)